{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T20:11:47Z","timestamp":1780344707564,"version":"3.54.1"},"reference-count":50,"publisher":"Elsevier BV","issue":"32","license":[{"start":{"date-parts":[[2020,7,1]],"date-time":"2020-07-01T00:00:00Z","timestamp":1593561600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,7,1]],"date-time":"2020-07-01T00:00:00Z","timestamp":1593561600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2020,5,18]],"date-time":"2020-05-18T00:00:00Z","timestamp":1589760000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100000865","name":"Bill and Melinda Gates Foundation","doi-asserted-by":"publisher","award":["OPP1060394"],"award-info":[{"award-number":["OPP1060394"]}],"id":[{"id":"10.13039\/100000865","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000865","name":"Bill and Melinda Gates Foundation","doi-asserted-by":"publisher","award":["OPP1119024"],"award-info":[{"award-number":["OPP1119024"]}],"id":[{"id":"10.13039\/100000865","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003074","name":"Agencia Nacional de Promoci\u00f3n Cient\u00edfica y Tecnol\u00f3gica","doi-asserted-by":"publisher","award":["PICT 2013 No"],"award-info":[{"award-number":["PICT 2013 No"]}],"id":[{"id":"10.13039\/501100003074","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003074","name":"Agencia Nacional de Promoci\u00f3n Cient\u00edfica y Tecnol\u00f3gica","doi-asserted-by":"publisher","award":["PICT 2016 No"],"award-info":[{"award-number":["PICT 2016 No"]}],"id":[{"id":"10.13039\/501100003074","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Vaccine"],"published-print":{"date-parts":[[2020,7]]},"DOI":"10.1016\/j.vaccine.2020.05.039","type":"journal-article","created":{"date-parts":[[2020,6,11]],"date-time":"2020-06-11T22:35:46Z","timestamp":1591914946000},"page":"5027-5035","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":7,"title":["U-Omp19 from Brucella abortus increases dmLT immunogenicity and improves protection against Escherichia coli heat-labile toxin (LT) oral challenge"],"prefix":"10.1016","volume":"38","author":[{"given":"Lorena M.","family":"Coria","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Franco L.","family":"Martinez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laura A.","family":"Bruno","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Karina A.","family":"Pasquevich","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7122-869X","authenticated-orcid":false,"given":"Juliana","family":"Cassataro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.vaccine.2020.05.039_b0005","doi-asserted-by":"crossref","unstructured":"Hosangadi D, Smith PG, Kaslow DC, Giersing BK, Who E, Shigella Vaccine Consultation Expert G. WHO consultation on ETEC and Shigella burden of disease, Geneva, 6-7th April 2017: Meeting report. Vaccine; 2018.","DOI":"10.1016\/j.vaccine.2017.10.011"},{"key":"10.1016\/j.vaccine.2020.05.039_b0010","doi-asserted-by":"crossref","first-page":"6783","DOI":"10.1016\/j.vaccine.2017.07.036","article-title":"Global burden of diarrheal diseases among children in developing countries: Incidence, etiology, and insights from new molecular diagnostic techniques","volume":"35","author":"Kotloff","year":"2017","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2020.05.039_b0015","doi-asserted-by":"crossref","first-page":"465","DOI":"10.1128\/CMR.18.3.465-483.2005","article-title":"Enterotoxigenic Escherichia coli in developing countries: epidemiology, microbiology, clinical features, treatment, and prevention","volume":"18","author":"Qadri","year":"2005","journal-title":"Clin Microbiol Rev"},{"issue":"Suppl 3","key":"10.1016\/j.vaccine.2020.05.039_b0020","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1007\/s00508-009-1228-1","article-title":"Travellers' diarrhoea - pros and cons of different prophylactic measures","volume":"121","author":"Wagner","year":"2009","journal-title":"Wien Klin Wochenschr"},{"key":"10.1016\/j.vaccine.2020.05.039_b0025","first-page":"CD009029","article-title":"Vaccines for preventing enterotoxigenic Escherichia coli (ETEC) diarrhoea","author":"Ahmed","year":"2013","journal-title":"Cochr Database Syst Rev"},{"key":"10.1016\/j.vaccine.2020.05.039_b0030","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1038\/nrmicro2265","article-title":"Molecular mechanisms of Escherichia coli pathogenicity","volume":"8","author":"Croxen","year":"2010","journal-title":"Nat Rev Microbiol"},{"key":"10.1016\/j.vaccine.2020.05.039_b0035","doi-asserted-by":"crossref","first-page":"S6","DOI":"10.1093\/jtm\/taw090","article-title":"Resistant pathogens as causes of traveller's diarrhea globally and impact(s) on treatment failure and recommendations","volume":"24","author":"Tribble","year":"2017","journal-title":"J Travel Med"},{"key":"10.1016\/j.vaccine.2020.05.039_b0040","doi-asserted-by":"crossref","first-page":"6167","DOI":"10.1016\/j.vaccine.2011.06.084","article-title":"A systematic review of ETEC epidemiology focusing on colonization factor and toxin expression","volume":"29","author":"Isidean","year":"2011","journal-title":"Vaccine."},{"key":"10.1016\/j.vaccine.2020.05.039_b0045","doi-asserted-by":"crossref","first-page":"795","DOI":"10.1586\/14760584.7.6.795","article-title":"Vaccines against enterotoxigenic Escherichia coli","volume":"7","author":"Svennerholm","year":"2008","journal-title":"Exp Rev Vacc"},{"key":"10.1016\/j.vaccine.2020.05.039_b0050","doi-asserted-by":"crossref","first-page":"4768","DOI":"10.1016\/j.vaccine.2019.02.070","article-title":"Vaccines Against Shigella and Enterotoxigenic Escherichia coli: A summary of the 2018 VASE Conference","volume":"37","author":"Barry","year":"2019","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2020.05.039_b0055","doi-asserted-by":"crossref","first-page":"3311","DOI":"10.1128\/IAI.66.7.3311-3316.1998","article-title":"Intestinal immune responses to an inactivated oral enterotoxigenic Escherichia coli vaccine and associated immunoglobulin A responses in blood","volume":"66","author":"Ahren","year":"1998","journal-title":"Infect Immun"},{"key":"10.1016\/j.vaccine.2020.05.039_b0060","doi-asserted-by":"crossref","first-page":"495","DOI":"10.1586\/erv.12.12","article-title":"Recent progress toward an enterotoxigenic Escherichia coli vaccine","volume":"11","author":"Svennerholm","year":"2012","journal-title":"Exp Rev Vacc"},{"key":"10.1016\/j.vaccine.2020.05.039_b0065","doi-asserted-by":"crossref","first-page":"628","DOI":"10.1128\/CVI.00248-16","article-title":"Immunogenicity and Protective Efficacy against Enterotoxigenic Escherichia coli Colonization following Intradermal, Sublingual, or Oral Vaccination with EtpA Adhesin","volume":"23","author":"Luo","year":"2016","journal-title":"Clin Vacc Immunol: CVI"},{"key":"10.1016\/j.vaccine.2020.05.039_b0070","doi-asserted-by":"crossref","first-page":"5869","DOI":"10.1016\/j.vaccine.2011.05.021","article-title":"A systematic review of experimental infections with enterotoxigenic Escherichia coli (ETEC)","volume":"29","author":"Porter","year":"2011","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2020.05.039_b0075","doi-asserted-by":"crossref","first-page":"658","DOI":"10.1111\/j.1651-2227.1988.tb10726.x","article-title":"Breast milk anti-Escherichia coli heat-labile toxin IgA antibodies protect against toxin-induced infantile diarrhea","volume":"77","author":"Cruz","year":"1988","journal-title":"Acta Paediatr Scand"},{"key":"10.1016\/j.vaccine.2020.05.039_b0080","doi-asserted-by":"crossref","first-page":"3961","DOI":"10.1128\/IAI.00459-07","article-title":"Disease burden due to enterotoxigenic Escherichia coli in the first 2 years of life in an urban community in Bangladesh","volume":"75","author":"Qadri","year":"2007","journal-title":"Infect Immun"},{"key":"10.1016\/j.vaccine.2020.05.039_b0085","first-page":"370","article-title":"Prevalence of enterotoxigenic Escherichia coli-associated diarrhoea and carrier state in the developing world","volume":"22","author":"Wenneras","year":"2004","journal-title":"J Health Popul Nutr"},{"key":"10.1016\/j.vaccine.2020.05.039_b0090","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pntd.0002822","article-title":"Antigen-specific memory B-cell responses to enterotoxigenic Escherichia coli infection in Bangladeshi adults","volume":"8","author":"Alam","year":"2014","journal-title":"PLoS Negl Trop Dis"},{"key":"10.1016\/j.vaccine.2020.05.039_b0095","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1016\/0264-410X(88)90223-X","article-title":"Adjuvant activity of Escherichia coli heat-labile enterotoxin and effect on the induction of oral tolerance in mice to unrelated protein antigens","volume":"6","author":"Clements","year":"1988","journal-title":"Vaccine."},{"key":"10.1016\/j.vaccine.2020.05.039_b0100","doi-asserted-by":"crossref","unstructured":"Clements JD, Norton EB. The Mucosal Vaccine Adjuvant LT(R192G\/L211A) or dmLT. mSphere. 2018;3.","DOI":"10.1128\/mSphere.00215-18"},{"key":"10.1016\/j.vaccine.2020.05.039_b0105","doi-asserted-by":"crossref","first-page":"546","DOI":"10.1128\/CVI.00538-10","article-title":"Characterization of a mutant Escherichia coli heat-labile toxin, LT(R192G\/L211A), as a safe and effective oral adjuvant","volume":"18","author":"Norton","year":"2011","journal-title":"Clin Vacc Immunol: CVI"},{"key":"10.1016\/j.vaccine.2020.05.039_b0110","doi-asserted-by":"crossref","first-page":"7077","DOI":"10.1016\/j.vaccine.2014.10.069","article-title":"Safety and immunogenicity of an improved oral inactivated multivalent enterotoxigenic Escherichia coli (ETEC) vaccine administered alone and together with dmLT adjuvant in a double-blind, randomized, placebo-controlled Phase I study","volume":"32","author":"Lundgren","year":"2014","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2020.05.039_b0115","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0136302","article-title":"Evaluating the A-Subunit of the Heat-Labile Toxin (LT) As an Immunogen and a Protective Antigen Against Enterotoxigenic Escherichia coli (ETEC)","volume":"10","author":"Norton","year":"2015","journal-title":"PLoS ONE"},{"key":"10.1016\/j.vaccine.2020.05.039_b0120","doi-asserted-by":"crossref","first-page":"2457","DOI":"10.1016\/j.vaccine.2013.03.027","volume":"31","author":"Holmgren","year":"2013","journal-title":"Vaccine."},{"key":"10.1016\/j.vaccine.2020.05.039_b0125","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0142090","article-title":"Immunization with a Double-Mutant (R192G\/L211A) of the Heat-Labile Enterotoxin of Escherichia coli Offers Partial Protection against Campylobacter jejuni in an Adult Mouse Intestinal Colonization Model","volume":"10","author":"Albert","year":"2015","journal-title":"PLoS ONE"},{"key":"10.1016\/j.vaccine.2020.05.039_b0130","doi-asserted-by":"crossref","DOI":"10.1128\/IAI.00460-19","article-title":"Intradermal or sublingual delivery and heat-labile enterotoxin (LT) proteins shape immunologic outcomes to CFA\/I fimbriae-derived subunit antigen vaccine against enterotoxigenic E. coli","author":"Maciel","year":"2019","journal-title":"Infect Immun"},{"key":"10.1016\/j.vaccine.2020.05.039_b0135","doi-asserted-by":"crossref","first-page":"3132","DOI":"10.1016\/j.vaccine.2016.04.055","article-title":"Induction of long term mucosal immunological memory in humans by an oral inactivated multivalent enterotoxigenic Escherichia coli vaccine","volume":"34","author":"Lundgren","year":"2016","journal-title":"Vaccine."},{"key":"10.1016\/j.vaccine.2020.05.039_b0140","doi-asserted-by":"crossref","first-page":"1978","DOI":"10.1016\/j.vaccine.2019.02.025","article-title":"Live attenuated enterotoxigenic Escherichia coli (ETEC) vaccine with dmLT adjuvant protects human volunteers against virulent experimental ETEC challenge","volume":"37","author":"Harro","year":"2019","journal-title":"Vaccine."},{"key":"10.1016\/j.vaccine.2020.05.039_b0145","article-title":"Safety and immunogenicity of the oral, inactivated, enterotoxigenic Escherichia coli vaccine ETVAX in Bangladeshi children and infants: a double-blind, randomised, placebo-controlled phase 1\/2 trial","author":"Qadri","year":"2019","journal-title":"Lancet Infect Diseases"},{"key":"10.1016\/j.vaccine.2020.05.039_b0150","doi-asserted-by":"crossref","first-page":"419","DOI":"10.1080\/21645515.2019.1649555","volume":"16","author":"Seo","year":"2020","journal-title":"Hum Vaccin Immunother."},{"key":"10.1016\/j.vaccine.2020.05.039_b0155","doi-asserted-by":"crossref","first-page":"1764","DOI":"10.1128\/CVI.00464-13","article-title":"Safety and immunogenicity of a single oral dose of recombinant double mutant heat-labile toxin derived from enterotoxigenic Escherichia coli","volume":"20","author":"El-Kamary","year":"2013","journal-title":"Clin Vaccine Immunol: CVI."},{"key":"10.1016\/j.vaccine.2020.05.039_b0160","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0016203","article-title":"An oral vaccine based on U-Omp19 induces protection against B. abortus mucosal challenge by inducing an adaptive IL-17 immune response in mice","volume":"6","author":"Pasquevich","year":"2011","journal-title":"PLoS ONE"},{"key":"10.1016\/j.vaccine.2020.05.039_b0165","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1016\/j.jconrel.2015.10.011","article-title":"A bacterial protease inhibitor protects antigens delivered in oral vaccines from digestion while triggering specific mucosal immune responses","volume":"220","author":"Ibanez","year":"2015","journal-title":"J Controlled Release: Official J Control Release Soc"},{"key":"10.1016\/j.vaccine.2020.05.039_b0170","doi-asserted-by":"crossref","first-page":"4014","DOI":"10.4049\/jimmunol.1501188","article-title":"A Brucella spp. Protease Inhibitor Limits Antigen Lysosomal Proteolysis, Increases Cross-Presentation, and Enhances CD8+ T Cell Responses","volume":"196","author":"Coria","year":"2016","journal-title":"J Immunol"},{"key":"10.1016\/j.vaccine.2020.05.039_b0175","doi-asserted-by":"crossref","first-page":"430","DOI":"10.1016\/j.vaccine.2015.12.012","article-title":"Brucella abortus Omp19 recombinant protein subcutaneously co-delivered with an antigen enhances antigen-specific T helper 1 memory responses and induces protection against parasite challenge","volume":"34","author":"Coria","year":"2016","journal-title":"Vaccine."},{"key":"10.1016\/j.vaccine.2020.05.039_b0180","doi-asserted-by":"crossref","first-page":"171","DOI":"10.3389\/fimmu.2017.00171","article-title":"U-Omp19 from Brucella abortus Is a Useful Adjuvant for Vaccine Formulations against Salmonella Infection in Mice","volume":"8","author":"Risso","year":"2017","journal-title":"Front Immunol"},{"key":"10.1016\/j.vaccine.2020.05.039_b0185","doi-asserted-by":"crossref","first-page":"158","DOI":"10.1016\/j.jconrel.2018.11.025","article-title":"Oral co-administration of a bacterial protease inhibitor in the vaccine formulation increases antigen delivery at the intestinal epithelial barrier","volume":"293","author":"Coria","year":"2019","journal-title":"J Control Release."},{"key":"10.1016\/j.vaccine.2020.05.039_b0190","doi-asserted-by":"crossref","first-page":"436","DOI":"10.1128\/IAI.01151-08","article-title":"Immunization with recombinant Brucella species outer membrane protein Omp16 or Omp19 in adjuvant induces specific CD4+ and CD8+ T cells as well as systemic and oral protection against Brucella abortus infection","volume":"77","author":"Pasquevich","year":"2009","journal-title":"Infect Immun"},{"key":"10.1016\/j.vaccine.2020.05.039_b0195","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1128\/CVI.00521-12","article-title":"Study of avidity of antigen-specific antibody as a means of understanding development of long-term immunological memory after Vibrio cholerae O1 infection","volume":"20","author":"Alam","year":"2013","journal-title":"Clin Vacc Immunol: CVI"},{"key":"10.1016\/j.vaccine.2020.05.039_b0200","doi-asserted-by":"crossref","first-page":"2426","DOI":"10.1128\/IAI.00181-12","article-title":"The A subunit of Escherichia coli heat-labile enterotoxin functions as a mucosal adjuvant and promotes IgG2a, IgA, and Th17 responses to vaccine antigens","volume":"80","author":"Norton","year":"2012","journal-title":"Infect Immun"},{"key":"10.1016\/j.vaccine.2020.05.039_b0205","doi-asserted-by":"crossref","first-page":"869","DOI":"10.1128\/IAI.74.2.869-875.2006","article-title":"Importance of heat-labile enterotoxin in colonization of the adult mouse small intestine by human enterotoxigenic Escherichia coli strains","volume":"74","author":"Allen","year":"2006","journal-title":"Infect Immun"},{"key":"10.1016\/j.vaccine.2020.05.039_b0210","doi-asserted-by":"crossref","first-page":"602","DOI":"10.1016\/j.vaccine.2018.12.011","article-title":"A Phase 1 dose escalating study of double mutant heat-labile toxin LTR192G\/L211A (dmLT) from Enterotoxigenic Escherichia coli (ETEC) by sublingual or oral immunization","volume":"37","author":"Bernstein","year":"2019","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2020.05.039_b0215","doi-asserted-by":"crossref","first-page":"677","DOI":"10.1586\/erv.12.37","article-title":"Progress and hurdles in the development of vaccines against enterotoxigenic Escherichia coli in humans","volume":"11","author":"Zhang","year":"2012","journal-title":"Exp Rev Vacc"},{"key":"10.1016\/j.vaccine.2020.05.039_b0220","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1002\/hep.510300218","article-title":"The immunobiology of bile and biliary epithelium","volume":"30","author":"Reynoso-Paz","year":"1999","journal-title":"Hepatology"},{"key":"10.1016\/j.vaccine.2020.05.039_b0225","doi-asserted-by":"crossref","first-page":"2395","DOI":"10.1084\/jem.20100995","article-title":"A requirement for FcgammaR in antibody-mediated bacterial toxin neutralization","volume":"207","author":"Abboud","year":"2010","journal-title":"J Exp Med"},{"key":"10.1016\/j.vaccine.2020.05.039_b0230","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1038\/s41541-019-0116-6","article-title":"The TLR4 agonist adjuvant SLA-SE promotes functional mucosal antibodies against a parenterally delivered ETEC vaccine","volume":"4","author":"Liang","year":"2019","journal-title":"npj Vaccines"},{"key":"10.1016\/j.vaccine.2020.05.039_b0235","doi-asserted-by":"crossref","first-page":"1987","DOI":"10.1080\/21645515.2018.1454571","article-title":"Analysis of the dose-sparing effect of adjuvanted Sabin-inactivated poliovirus vaccine (sIPV)","volume":"14","author":"Li","year":"2018","journal-title":"Human Vacc Immunotherapeut"},{"key":"10.1016\/j.vaccine.2020.05.039_b0240","doi-asserted-by":"crossref","first-page":"2037","DOI":"10.1016\/j.vaccine.2011.01.012","article-title":"Preclinical evaluation of the saponin derivative GPI-0100 as an immunostimulating and dose-sparing adjuvant for pandemic influenza vaccines","volume":"29","author":"Liu","year":"2011","journal-title":"Vaccine."},{"key":"10.1016\/j.vaccine.2020.05.039_b0245","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.cimid.2015.09.002","article-title":"Heat-labile enterotoxin of Escherichia coli promotes intestinal colonization of Salmonella enterica","volume":"43","author":"Verbrugghe","year":"2015","journal-title":"Comp Immunol Microbiol Infect Dis"},{"key":"10.1016\/j.vaccine.2020.05.039_b0250","doi-asserted-by":"crossref","first-page":"2880","DOI":"10.1016\/j.vaccine.2016.02.076","article-title":"Status of vaccine research and development for enterotoxigenic Escherichia coli","volume":"34","author":"Bourgeois","year":"2016","journal-title":"Vaccine"}],"container-title":["Vaccine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X20306708?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X20306708?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,2]],"date-time":"2025-10-02T10:43:48Z","timestamp":1759401828000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0264410X20306708"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,7]]},"references-count":50,"journal-issue":{"issue":"32","published-print":{"date-parts":[[2020,7]]}},"alternative-id":["S0264410X20306708"],"URL":"https:\/\/doi.org\/10.1016\/j.vaccine.2020.05.039","relation":{},"ISSN":["0264-410X"],"issn-type":[{"value":"0264-410X","type":"print"}],"subject":[],"published":{"date-parts":[[2020,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"U-Omp19 from Brucella abortus increases dmLT immunogenicity and improves protection against Escherichia coli heat-labile toxin (LT) oral challenge","name":"articletitle","label":"Article Title"},{"value":"Vaccine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.vaccine.2020.05.039","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2020 The Authors. Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}]}}